EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Window of opportunity study measuring defactinib and avutometinib delivery in glioblastomas

Miguel Mayol Del Valle, Emely Morales Colon, Kavitha Kettimuthu, Kristal Maner-Smith, Jeffrey J Olson, Lilia Y Kucheryavykh

Cancer Chemotherapy and Pharmacology · 06.03.2026 · 96 (1)

DOI: 10.1007/s00280-026-04870-4 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 06.03.2026. Verfasst von Miguel Mayol Del Valle und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Benzamides, Brain Neoplasms, Glioblastoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Puerto Rico Science, Technology & Research Trust, Verastem Incorporated.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsBenzamidesBrain NeoplasmsGlioblastomaProtein Kinase InhibitorsAdultAgedFemaleHumansMaleMiddle AgedDose-Response Relationship, DrugPyrazinesSulfonamides

Stichwörter der Autor:innen

AvutometinibDefactinibGlioblastomaWindow of opportunity

Substanzen

Antineoplastic AgentsBenzamidesdefactinibProtein Kinase InhibitorsPyrazinesSulfonamides

Autor:innen und Institutionen

  • Department of Neurosurgery, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, USA.
  • Department of Biochemistry, Universidad Central del Caribe, Bayamon, PR, USA.
  • Emory Integrated Metabolomics and Lipidomics Core, Emory University School of Medicine, Atlanta, GA, USA.
  • Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA.
  • Department of Biochemistry, Universidad Central del Caribe, Bayamon, PR, USA. lilia.kucheryavykh@uccaribe.edu.

Förderung

  • Puerto Rico Science, Technology & Research Trust
  • Verastem Incorporated

Zitieren

APA

Del Valle, M. M., Colon, E. M., Kettimuthu, K., Maner-Smith, K., Olson, J. J., & Kucheryavykh, L. Y. (2026). Window of opportunity study measuring defactinib and avutometinib delivery in glioblastomas. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04870-4

Vancouver

Del Valle MM, Colon EM, Kettimuthu K, Maner-Smith K, Olson JJ, Kucheryavykh LY. Window of opportunity study measuring defactinib and avutometinib delivery in glioblastomas. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04870-4

BibTeX
@article{DelValle2026,
  author = {Del Valle, Miguel Mayol and Colon, Emely Morales and Kettimuthu, Kavitha and Maner-Smith, Kristal and Olson, Jeffrey J and Kucheryavykh, Lilia Y},
  title = {Window of opportunity study measuring defactinib and avutometinib delivery in glioblastomas},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2026},
  volume = {96},
  number = {1},
  doi = {10.1007/s00280-026-04870-4}
}
Kostenlos starten →